$NBSE News

Last published 2y ago

2y agoNBSENeuBase Therapeutics Announces Receipt of Notice from NasdaqGlobeNewswirePITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today reported that it received a notice (the "Notice) on April 4, 2024 from the Listing
2y agoNBSE PMDPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceGlobeNewswireACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice
3y agoNBSENeuBase Therapeutics Issues Statement Regarding Filing By ShareholderGlobeNewswirePITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and
3y agoNBSESYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASEPR NewswireURGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO, Sept. 6, 2023 /CNW/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics
3y agoNBSENeuBase Therapeutics to Explore Strategic AlternativesGlobeNewswirePITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
3y agoNBSENeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswirePITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
3y agoNBSENeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to RedosingGlobeNewswireNew preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to successfully
3y agoNBSENeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswirePITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
3y agoNBSENeuBase Announces 1-for-20 Reverse Stock SplitGlobeNewswirePITTSBURGH, June 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
3y agoNBSENeuBase to Participate in Jefferies Healthcare ConferenceGlobeNewswirePITTSBURGH, May 24, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
3y agoNBSENeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™GlobeNewswireData show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machineryData show that Stealth Editors™ do not elicit a
3y agoNBSENeuBase Announces Formation of Gene Editing Advisory BoardGlobeNewswirePITTSBURGH, May 16, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without
3y agoNBSENeuBase Reports Business Update and Financial Results for the First Quarter of 2023GlobeNewswireAnnounced oral presentations at the American Society of Gene & Cell Therapy ("ASGCT") 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at
3y agoNBSENeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual MeetingGlobeNewswirePITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene
3y agoNBSENeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023GlobeNewswirePITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level
3y agoNBSENeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022GlobeNewswirePITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level
4y agoNBSENeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare CompanyGlobeNewswirePITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level
4y agoNBSENeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene EditingGlobeNewswireWorkforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company's cash runway into Q2 CY2024The Company plans to maximize shareholder value by focusing R&D resources
4y agoNBSENeuBase to Participate at Chardan's 6th Annual Genetic Medicines ConferenceGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of
4y agoNBSENeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022GlobeNewswireLead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting a
4y agoNBSENeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COOGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of
4y agoNBSENeuBase to Participate at the Jefferies Healthcare ConferenceGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of
4y agoNBSENeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment SolutionGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of p
4y agoNBSENeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022GlobeNewswireInvestigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company's lead myotonic dystrophy type 1 (DM1) candidate; new preclinical data to be presented at the American Society of Gene an
4y agoNBSENeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual MeetingGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of p
4y agoNBSENeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia ReversalGlobeNewswireA single intravenous dose of NeuBase's Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride channel (Clcn1) function, and durably reverses myotonia in the HSALR model Multiple subcutaneous doses
4y agoNBSENeuBase to Present at Oppenheimer's 32nd Annual Healthcare ConferenceGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class o
4y agoNBSENeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific ConferenceGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of
4y agoNBSENeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022GlobeNewswireInvestigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming
4y agoNBSENeuBase Therapeutics Appoints Todd P. Branning Chief Financial OfficerGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of
4y agoNBSENeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of DirectorsGlobeNewswirePITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of
4y agoNBSENeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021GlobeNewswireValidated ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies; the Company's delivery shuttle enables pharmacology across programs in multiple tissues, including
5y agoNBSENeuBase to Present at the Jefferies London Healthcare ConferenceGlobeNewswirePITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic med
5y agoNBSE VBLTVBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United StatesGlobeNewswireTEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate financ
5y agoNBSENeuBase to Participate at the Chardan 5th Annual Genetic Medicines ConferenceGlobeNewswirePITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announce
5y agoNBSENeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewswirePITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic me
5y agoNBSENeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology OfficerGlobeNewswirePITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic me
5y agoNBSENeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswirePITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic me
5y agoNBSENeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating HighlightsGlobeNewswireFurther demonstrated broad potential of novel genetic medicine platform with in vivo data in three diseases driven by different genetic mechanisms of disease Presented preclinical data showing compounds enabled with NeuBase's proprietary delivery techn
5y agoNBSENeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor GrowthGlobeNewswireData presented today at NeuBase's R&D Day show functional rescue of myotonic dystrophy type 1 (DM1) phenotype in vivo after subcutaneous dosing; positions program to enter the clinic in CY 2022 Company also presented data demonstrating selective reduct
5y agoNBSENeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8thGlobeNewswireCompany to present new preclinical data in myotonic dystrophy type 1 to support a path to enter the clinic in 2022, as well as provide updates on the Huntington's disease program and unveil a new oncology program targeting high-value genetic driver muta
5y agoNBSENeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy OfficerGlobeNewswirePITTSBURGH, May 25, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appoin
5y agoNBSENeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical OfficerGlobeNewswirePITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appoin
5y agoNBSENeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021GlobeNewswireRBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19 Oppenheimer Rare & Orphan Disease Summit presentation on May 21 PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NB
5y agoNBSENeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021GlobeNewswireExtended cash runway into CY2023 following completion of an equity financing from leading healthcare investors generating $42.6 million in net proceeds; supports advancing the Company's lead program into the clinic and scaling of its precision genetic m
5y agoNBSENeuBase Therapeutics Appoints Gerald J. McDougall to Board of DirectorsGlobeNewswireProfessional dealmaker operating across the healthcare continuum to bring together key partners to translate scientific breakthroughs into commercial applications for the benefit of patients and society Creator and guide of strategic alliances, includi
5y agoNBSENeuBase Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience ConferenceGlobeNewswirePITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan,
5y agoNBSENeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswirePITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE), ("NeuBase"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the closing of its previo
5y agoNBSENeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common StockGlobeNewswirePITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwri
5y agoNBSENeuBase Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswirePITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an u